7/103 sources · 3 publishersUpdated Oct 8, 19:16 UTC
Curaleaf device gains Australian registration and New Zealand listing
Curaleaf International's Que Medical Inhalation Device gained registration in Australia and was listed for supply in New Zealand. The reusable device, developed with Jupiter Research, is intended to administer liquid Cannabis sativa extracts through inhalation and is registered in Australia as a Class IIb medical device.
Why it matters
The registrations create a compliant route for prescribers and patients to use Curaleaf's liquid cannabis delivery device in Australia and New Zealand. Curaleaf says the approvals support its broader international rollout of pharmaceutical-grade cannabinoid delivery technology.
Key facts
- 1Australia's Therapeutic Goods Administration registered QMID on 15 September 2026 in the Australian Register of Therapeutic Goods. prnewswire.com
- 2QMID was entered in New Zealand's WAND database on 17 September 2026. prnewswire.com
- 3The Australian register identifies QMID as a Class IIb medical device under ARTG number 531287. themarijuanaherald.com
- 4Curaleaf developed QMID with Jupiter Research LLC, which is listed as the device manufacturer in Australia. themarijuanaherald.com
- 5Curaleaf says QMID is available in seven countries. themarijuanaherald.com
Open questions
- The company did not disclose sales or revenue expectations for QMID's Australian or New Zealand availability.
Summary written by AlphAI from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.